nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—KCNH2—purkinje fiber—dilated cardiomyopathy	0.228	0.595	CbGeAlD
Alfuzosin—KCNH2—endocardium—dilated cardiomyopathy	0.117	0.306	CbGeAlD
Alfuzosin—Cardiac fibrillation—Lisinopril—dilated cardiomyopathy	0.0218	0.0505	CcSEcCtD
Alfuzosin—Bursitis—Lisinopril—dilated cardiomyopathy	0.0118	0.0273	CcSEcCtD
Alfuzosin—ADRA1D—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.0101	0.0544	CbGpPWpGaD
Alfuzosin—Cholestasis—Furosemide—dilated cardiomyopathy	0.01	0.0231	CcSEcCtD
Alfuzosin—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00987	0.0258	CbGeAlD
Alfuzosin—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00944	0.0218	CcSEcCtD
Alfuzosin—KCNH2—myocardium—dilated cardiomyopathy	0.00928	0.0243	CbGeAlD
Alfuzosin—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00912	0.0211	CcSEcCtD
Alfuzosin—ADRA1B—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00835	0.0451	CbGpPWpGaD
Alfuzosin—ADRA1D—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00815	0.0441	CbGpPWpGaD
Alfuzosin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00806	0.0186	CcSEcCtD
Alfuzosin—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00797	0.0184	CcSEcCtD
Alfuzosin—Laryngitis—Lisinopril—dilated cardiomyopathy	0.0079	0.0183	CcSEcCtD
Alfuzosin—Drowsiness—Spironolactone—dilated cardiomyopathy	0.0078	0.0181	CcSEcCtD
Alfuzosin—ADRA1A—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00741	0.0401	CbGpPWpGaD
Alfuzosin—KCNH2—Hematopoietic Stem Cell Differentiation—CSF3—dilated cardiomyopathy	0.00699	0.0378	CbGpPWpGaD
Alfuzosin—ADRA1B—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00676	0.0366	CbGpPWpGaD
Alfuzosin—ADRA1A—heart—dilated cardiomyopathy	0.00671	0.0175	CbGeAlD
Alfuzosin—KCNH2—heart—dilated cardiomyopathy	0.00648	0.0169	CbGeAlD
Alfuzosin—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00626	0.0145	CcSEcCtD
Alfuzosin—ADRA1A—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00601	0.0325	CbGpPWpGaD
Alfuzosin—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.0057	0.0132	CcSEcCtD
Alfuzosin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00566	0.0131	CcSEcCtD
Alfuzosin—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00554	0.0145	CbGeAlD
Alfuzosin—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00553	0.0128	CcSEcCtD
Alfuzosin—Malaise—Spironolactone—dilated cardiomyopathy	0.0055	0.0127	CcSEcCtD
Alfuzosin—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00535	0.0124	CcSEcCtD
Alfuzosin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00513	0.0119	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00503	0.0116	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00496	0.0115	CcSEcCtD
Alfuzosin—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00487	0.0113	CcSEcCtD
Alfuzosin—Injury—Lisinopril—dilated cardiomyopathy	0.0045	0.0104	CcSEcCtD
Alfuzosin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00443	0.0102	CcSEcCtD
Alfuzosin—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00436	0.0101	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0043	0.00994	CcSEcCtD
Alfuzosin—Arthritis—Lisinopril—dilated cardiomyopathy	0.00425	0.00984	CcSEcCtD
Alfuzosin—Drowsiness—Furosemide—dilated cardiomyopathy	0.00425	0.00982	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00423	0.0229	CbGpPWpGaD
Alfuzosin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00413	0.00956	CcSEcCtD
Alfuzosin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0041	0.00949	CcSEcCtD
Alfuzosin—Sweating—Furosemide—dilated cardiomyopathy	0.00407	0.00942	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00402	0.00929	CcSEcCtD
Alfuzosin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00395	0.00915	CcSEcCtD
Alfuzosin—KCNH2—Potassium Channels—ABCC9—dilated cardiomyopathy	0.00392	0.0212	CbGpPWpGaD
Alfuzosin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00378	0.00873	CcSEcCtD
Alfuzosin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00376	0.00871	CcSEcCtD
Alfuzosin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00374	0.00864	CcSEcCtD
Alfuzosin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00374	0.00864	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00372	0.00861	CcSEcCtD
Alfuzosin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00356	0.00824	CcSEcCtD
Alfuzosin—ADRA1D—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00356	0.0192	CbGpPWpGaD
Alfuzosin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00352	0.00815	CcSEcCtD
Alfuzosin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00348	0.00805	CcSEcCtD
Alfuzosin—Angiopathy—Furosemide—dilated cardiomyopathy	0.00346	0.008	CcSEcCtD
Alfuzosin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00344	0.00795	CcSEcCtD
Alfuzosin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00341	0.00788	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00332	0.00768	CcSEcCtD
Alfuzosin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00329	0.00761	CcSEcCtD
Alfuzosin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00329	0.00761	CcSEcCtD
Alfuzosin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00316	0.00732	CcSEcCtD
Alfuzosin—Rash—Spironolactone—dilated cardiomyopathy	0.00314	0.00726	CcSEcCtD
Alfuzosin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00314	0.00725	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00312	0.00722	CcSEcCtD
Alfuzosin—Headache—Spironolactone—dilated cardiomyopathy	0.00312	0.00721	CcSEcCtD
Alfuzosin—Jaundice—Lisinopril—dilated cardiomyopathy	0.00311	0.00718	CcSEcCtD
Alfuzosin—Sweating—Lisinopril—dilated cardiomyopathy	0.00305	0.00706	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00301	0.0163	CbGpPWpGaD
Alfuzosin—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00301	0.00697	CcSEcCtD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00299	0.0162	CbGpPWpGaD
Alfuzosin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00299	0.00691	CcSEcCtD
Alfuzosin—Vertigo—Furosemide—dilated cardiomyopathy	0.00298	0.0069	CcSEcCtD
Alfuzosin—Nausea—Spironolactone—dilated cardiomyopathy	0.00296	0.00684	CcSEcCtD
Alfuzosin—ADRA1B—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00295	0.016	CbGpPWpGaD
Alfuzosin—ADRA1D—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00288	0.0156	CbGpPWpGaD
Alfuzosin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00287	0.00663	CcSEcCtD
Alfuzosin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00284	0.00657	CcSEcCtD
Alfuzosin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00282	0.00653	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00281	0.00649	CcSEcCtD
Alfuzosin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.0028	0.00648	CcSEcCtD
Alfuzosin—Dry mouth—Furosemide—dilated cardiomyopathy	0.00276	0.00639	CcSEcCtD
Alfuzosin—Shock—Furosemide—dilated cardiomyopathy	0.00266	0.00616	CcSEcCtD
Alfuzosin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00266	0.00614	CcSEcCtD
Alfuzosin—Flushing—Lisinopril—dilated cardiomyopathy	0.00265	0.00614	CcSEcCtD
Alfuzosin—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00265	0.00613	CcSEcCtD
Alfuzosin—Skin disorder—Furosemide—dilated cardiomyopathy	0.00263	0.00608	CcSEcCtD
Alfuzosin—ADRA1A—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00262	0.0142	CbGpPWpGaD
Alfuzosin—ADRA1A—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.00262	0.0142	CbGpPWpGaD
Alfuzosin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00262	0.00606	CcSEcCtD
Alfuzosin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00259	0.006	CcSEcCtD
Alfuzosin—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00258	0.00596	CcSEcCtD
Alfuzosin—Hypotension—Furosemide—dilated cardiomyopathy	0.00253	0.00585	CcSEcCtD
Alfuzosin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00251	0.0058	CcSEcCtD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00248	0.0134	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00242	0.0131	CbGpPWpGaD
Alfuzosin—Back pain—Lisinopril—dilated cardiomyopathy	0.00241	0.00557	CcSEcCtD
Alfuzosin—Somnolence—Furosemide—dilated cardiomyopathy	0.00241	0.00557	CcSEcCtD
Alfuzosin—ADRA1B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00239	0.0129	CbGpPWpGaD
Alfuzosin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00234	0.00541	CcSEcCtD
Alfuzosin—Fatigue—Furosemide—dilated cardiomyopathy	0.00233	0.0054	CcSEcCtD
Alfuzosin—Constipation—Furosemide—dilated cardiomyopathy	0.00232	0.00536	CcSEcCtD
Alfuzosin—Pain—Furosemide—dilated cardiomyopathy	0.00232	0.00536	CcSEcCtD
Alfuzosin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00231	0.00534	CcSEcCtD
Alfuzosin—Angioedema—Lisinopril—dilated cardiomyopathy	0.00227	0.00526	CcSEcCtD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00225	0.0122	CbGpPWpGaD
Alfuzosin—Malaise—Lisinopril—dilated cardiomyopathy	0.00225	0.00519	CcSEcCtD
Alfuzosin—Vertigo—Lisinopril—dilated cardiomyopathy	0.00224	0.00517	CcSEcCtD
Alfuzosin—Syncope—Lisinopril—dilated cardiomyopathy	0.00223	0.00516	CcSEcCtD
Alfuzosin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00223	0.00516	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00221	0.00512	CcSEcCtD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.0022	0.0119	CbGpPWpGaD
Alfuzosin—Palpitations—Lisinopril—dilated cardiomyopathy	0.0022	0.00509	CcSEcCtD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00219	0.0118	CbGpPWpGaD
Alfuzosin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00219	0.00506	CcSEcCtD
Alfuzosin—Urticaria—Furosemide—dilated cardiomyopathy	0.00215	0.00498	CcSEcCtD
Alfuzosin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00214	0.00495	CcSEcCtD
Alfuzosin—ADRA1A—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00212	0.0115	CbGpPWpGaD
Alfuzosin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00212	0.0049	CcSEcCtD
Alfuzosin—Chest pain—Lisinopril—dilated cardiomyopathy	0.00212	0.0049	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.0021	0.00487	CcSEcCtD
Alfuzosin—Discomfort—Lisinopril—dilated cardiomyopathy	0.00209	0.00484	CcSEcCtD
Alfuzosin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00207	0.00479	CcSEcCtD
Alfuzosin—Oedema—Lisinopril—dilated cardiomyopathy	0.00203	0.0047	CcSEcCtD
Alfuzosin—Infection—Lisinopril—dilated cardiomyopathy	0.00202	0.00467	CcSEcCtD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00201	0.0109	CbGpPWpGaD
Alfuzosin—Shock—Lisinopril—dilated cardiomyopathy	0.002	0.00462	CcSEcCtD
Alfuzosin—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00199	0.0046	CcSEcCtD
Alfuzosin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00198	0.00459	CcSEcCtD
Alfuzosin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00197	0.00457	CcSEcCtD
Alfuzosin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00196	0.00454	CcSEcCtD
Alfuzosin—Asthenia—Furosemide—dilated cardiomyopathy	0.00194	0.00449	CcSEcCtD
Alfuzosin—Pruritus—Furosemide—dilated cardiomyopathy	0.00192	0.00443	CcSEcCtD
Alfuzosin—Hypotension—Lisinopril—dilated cardiomyopathy	0.0019	0.00439	CcSEcCtD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00187	0.0101	CbGpPWpGaD
Alfuzosin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00185	0.00429	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00185	0.00428	CcSEcCtD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00182	0.00983	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00182	0.00981	CbGpPWpGaD
Alfuzosin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00181	0.00418	CcSEcCtD
Alfuzosin—Dizziness—Furosemide—dilated cardiomyopathy	0.00179	0.00414	CcSEcCtD
Alfuzosin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00179	0.00414	CcSEcCtD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00179	0.00966	CbGpPWpGaD
Alfuzosin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00175	0.00406	CcSEcCtD
Alfuzosin—Fatigue—Lisinopril—dilated cardiomyopathy	0.00175	0.00405	CcSEcCtD
Alfuzosin—Pain—Lisinopril—dilated cardiomyopathy	0.00174	0.00402	CcSEcCtD
Alfuzosin—Constipation—Lisinopril—dilated cardiomyopathy	0.00174	0.00402	CcSEcCtD
Alfuzosin—Vomiting—Furosemide—dilated cardiomyopathy	0.00172	0.00398	CcSEcCtD
Alfuzosin—KCNH2—Neuronal System—ABCC9—dilated cardiomyopathy	0.00171	0.00926	CbGpPWpGaD
Alfuzosin—Rash—Furosemide—dilated cardiomyopathy	0.00171	0.00395	CcSEcCtD
Alfuzosin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00171	0.00395	CcSEcCtD
Alfuzosin—Headache—Furosemide—dilated cardiomyopathy	0.0017	0.00392	CcSEcCtD
Alfuzosin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00167	0.00387	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00166	0.00384	CcSEcCtD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00166	0.00897	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—ACTN2—dilated cardiomyopathy	0.00164	0.00888	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00163	0.00882	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00161	0.00873	CbGpPWpGaD
Alfuzosin—Urticaria—Lisinopril—dilated cardiomyopathy	0.00161	0.00373	CcSEcCtD
Alfuzosin—Nausea—Furosemide—dilated cardiomyopathy	0.00161	0.00372	CcSEcCtD
Alfuzosin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00161	0.00372	CcSEcCtD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00151	0.00815	CbGpPWpGaD
Alfuzosin—Asthenia—Lisinopril—dilated cardiomyopathy	0.00146	0.00337	CcSEcCtD
Alfuzosin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00144	0.00333	CcSEcCtD
Alfuzosin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00139	0.00322	CcSEcCtD
Alfuzosin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00134	0.00311	CcSEcCtD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00134	0.00724	CbGpPWpGaD
Alfuzosin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00129	0.00299	CcSEcCtD
Alfuzosin—Rash—Lisinopril—dilated cardiomyopathy	0.00128	0.00296	CcSEcCtD
Alfuzosin—ADRA1D—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00128	0.00692	CbGpPWpGaD
Alfuzosin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00128	0.00296	CcSEcCtD
Alfuzosin—Headache—Lisinopril—dilated cardiomyopathy	0.00127	0.00294	CcSEcCtD
Alfuzosin—Nausea—Lisinopril—dilated cardiomyopathy	0.00121	0.00279	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00118	0.00636	CbGpPWpGaD
Alfuzosin—ADRA1D—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.00116	0.00627	CbGpPWpGaD
Alfuzosin—ADRA1B—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00114	0.00616	CbGpPWpGaD
Alfuzosin—ADRA1A—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.00109	0.00591	CbGpPWpGaD
Alfuzosin—ADRA1B—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.00109	0.00591	CbGpPWpGaD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.00106	0.00576	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00102	0.00552	CbGpPWpGaD
Alfuzosin—ADRA1A—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00101	0.00547	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000963	0.00521	CbGpPWpGaD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000884	0.00478	CbGpPWpGaD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000879	0.00475	CbGpPWpGaD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000863	0.00466	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000855	0.00462	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000785	0.00424	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000762	0.00412	CbGpPWpGaD
Alfuzosin—ADRA1D—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000758	0.0041	CbGpPWpGaD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.00073	0.00394	CbGpPWpGaD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000716	0.00387	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000709	0.00383	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000686	0.00371	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000678	0.00367	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000653	0.00353	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000653	0.00353	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000648	0.0035	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000636	0.00344	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000633	0.00342	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000629	0.0034	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000607	0.00328	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000588	0.00318	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000588	0.00318	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000586	0.00317	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00057	0.00308	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000563	0.00304	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000562	0.00304	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000559	0.00302	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000556	0.00301	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000542	0.00293	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000542	0.00293	CbGpPWpGaD
Alfuzosin—ADRA1D—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000534	0.00289	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000522	0.00282	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000506	0.00274	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000504	0.00272	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000502	0.00272	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.0005	0.0027	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000497	0.00269	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000497	0.00269	CbGpPWpGaD
Alfuzosin—ADRA1B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000497	0.00269	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000488	0.00264	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000486	0.00263	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000481	0.0026	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000481	0.0026	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000477	0.00258	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000476	0.00258	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000462	0.0025	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000462	0.0025	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000448	0.00242	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000448	0.00242	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000443	0.00239	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000434	0.00234	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000432	0.00234	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000417	0.00225	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000413	0.00223	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000413	0.00223	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00041	0.00222	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000396	0.00214	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000395	0.00214	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000393	0.00213	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000388	0.0021	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000384	0.00207	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000382	0.00207	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—RAF1—dilated cardiomyopathy	0.000374	0.00202	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000372	0.00201	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00037	0.002	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000367	0.00198	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000367	0.00198	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000363	0.00196	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000353	0.00191	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000352	0.0019	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000351	0.0019	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000341	0.00184	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000331	0.00179	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00033	0.00178	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000317	0.00172	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000301	0.00163	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000293	0.00159	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000282	0.00152	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000281	0.00152	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000281	0.00152	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000275	0.00149	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000269	0.00146	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000267	0.00145	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000261	0.00141	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000261	0.00141	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000255	0.00138	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000255	0.00138	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000253	0.00137	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000244	0.00132	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000237	0.00128	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000233	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000233	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00023	0.00124	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000227	0.00123	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000223	0.00121	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000217	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000216	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000212	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000212	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00021	0.00114	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000207	0.00112	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000207	0.00112	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000205	0.00111	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000198	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000197	0.00106	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000196	0.00106	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000193	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000191	0.00103	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000189	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000188	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000188	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000187	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000186	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000179	0.00097	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000175	0.000946	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00017	0.00092	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00017	0.000918	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000169	0.000916	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000167	0.000905	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000163	0.000881	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000159	0.000861	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000159	0.000861	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000155	0.000836	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000152	0.000822	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000151	0.000817	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000151	0.000815	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000151	0.000815	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000145	0.000782	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000145	0.000782	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000141	0.000762	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000141	0.00076	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00014	0.000758	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000138	0.000747	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000137	0.000742	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000136	0.000734	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000132	0.000715	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000132	0.000714	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000126	0.000682	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000125	0.000677	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000125	0.000677	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000125	0.000677	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.00012	0.000649	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.00012	0.000646	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000117	0.000634	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000116	0.000629	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000116	0.000627	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000115	0.00062	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000113	0.000609	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000112	0.000606	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000111	0.000601	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000111	0.000601	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00011	0.000595	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000107	0.000576	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000103	0.000559	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000102	0.00055	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.0001	0.000541	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.62e-05	0.00052	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.58e-05	0.000518	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.45e-05	0.000511	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.13e-05	0.000494	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.55e-05	0.000462	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RAC1—dilated cardiomyopathy	8.54e-05	0.000462	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AGT—dilated cardiomyopathy	8.16e-05	0.000441	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.11e-05	0.000438	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.95e-05	0.00043	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.84e-05	0.000424	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	7.09e-05	0.000383	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.07e-05	0.000382	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.97e-05	0.000377	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	6.77e-05	0.000366	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.57e-05	0.000355	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	6.29e-05	0.00034	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	6.01e-05	0.000325	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RAF1—dilated cardiomyopathy	5.66e-05	0.000306	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.46e-05	0.000295	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.85e-05	0.000262	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	4.7e-05	0.000254	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.17e-05	0.000226	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGFR—dilated cardiomyopathy	3.88e-05	0.00021	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.25e-05	0.000176	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.22e-05	0.000174	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.16e-05	0.000171	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.86e-05	0.000155	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.85e-05	0.000154	CbGpPWpGaD
